Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fenugreek fibre
- Development stage
- Discontinued
- Lead developer
- RDC Clinical
- Administration
- Oral
01
Overview
Fenugreek fibre is an investigational dietary supplement derived from the seeds of the fenugreek plant (*Trigonella foenum-graecum*). It is primarily composed of galactomannans, a type of soluble fiber known for its prebiotic properties. Developed by RDC Clinical Pty Ltd, the product was studied for its ability to modulate the gut microbiome in healthy adults with a BMI over 25 kg/m². The mechanism involves providing a fermentable substrate for gut bacteria, which may improve microbial diversity and metabolic health. However, the clinical trial (ACTRN12619000836112) intended to evaluate these effects was withdrawn before completion.
- Other names
- Trigonella foenum-graecum fibrefenugreek fiber
Beyond the preview
Go deeper on fenugreek fibre.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fenugreek fibre.